ENDE Biofrontera Investors Financial reports KEY FINANCIALS TEUR 2020 2019 2018 2017 Total revenue 30,346 31,265 21,107 12,025 Research and development costs (4,789) (4,636) (4,427) (4,225) General and administrative costs (9,150) (16,275) (12,963) (3,097) Sales costs (20,482) (28,856) (17,744) (16,922) Profit (loss) from operations (7,611) (23,377) (18,478) (13,934) Other (expenses) and income (2,418) 21,184 969 (1,073) Net loss before tax (12,697) (4,777) (19,269) (16,102) QUARTERLY REPORT 3RD QUARTER Q3/2021 HALF-YEAR FINANCIAL REPORT H1/2021 QUARTERLY REPORT 1ST QUARTER Q1/2021 ANNUAL REPORT 2020 AR 2020 ARCHIVE FINANCIAL REPORTS Financial reports 2020 Annual report 2020 Annual report according to HGB (German only) Quarterly report Q3 2020 Half-Year report 2020 Quarterly report Q1 2020 Financial reports 2019 Financial reports 2018 Financial reports 2017 Financial reports 2016 Financial reports 2015 Financial reports 2014 Financial reports 2013 CONTACT Biofrontera AG Hemmelrather Weg 201 51377 Leverkusen +49-214-87632-0 info@biofrontera.com Germany SERVICE Imprint Disclaimer Data Privacy Policy Terms and Conditions (German only) Purchasing conditions (German only) ABOUT BIOFRONTERA We have specialized in dermatology as your skin's health is our concern. We aim to protect and heal your skin with our innovative photodynamic therapy medication. BIOFRONTERA AG © 2021 all rights reserved This site uses third-party website tracking technologies to provide and continually improve our services, and to display advertisements according to users' interests. I agree and may revoke or change my consent at any time with effect for the future. DENY ACCEPT MORE Powered by